Ochsner Health is the leading nonprofit healthcare provider in the Gulf South. Ochsner inspires healthier lives and stronger communities through our mission to serve, heal, lead, educate and innovate.
Ochsner research leads groundbreaking findings for Multi-Cancer Early Detection (MCED)
Marc Matrana, MD, medical oncologist at the Ochsner Cancer Institute, was lead author of a new study on MCED
New Orleans - The Ochsner Cancer Institute is proud to announce its participation in a pivotal research study that evaluates the real-world performance of the Galleri® multi-cancer early detection (MCED) test. This innovative blood test analyzes DNA patterns in healthy individuals to detect cancer signals and predict their origin, offering a transformative approach to early cancer diagnosis.
Entitled “Real-world data and clinical experience from over 100,000 multi-cancer early detection tests,” the study was recently published in Nature Communications. Marc Matrana, MD, medical oncologist at the Ochsner Cancer Institute, was lead author of the publication.
Study Overview
The study evaluated the Galleri® MCED test across a large cohort of 111,080 participants in real-world healthcare settings, including private practices, healthcare systems and telemedicine. By analyzing methylation patterns in cell-free DNA, the test aims to detect cancer signals and predict their anatomical origin, enabling earlier and more efficient diagnostic evaluations. Ochsner’s involvement in this research highlights its commitment to advancing innovative diagnostic tools that improve patient outcomes.
Key Findings
These findings highlight the potential of the Galleri® MCED test to enable faster and more efficient diagnostic evaluations:
Cancer detection rate: 0.91% (1,011 cancers detected out of 111,080 participants).
Accuracy of cancer signal origin (CSO) prediction: Impressive 87% accuracy of cases with a reported cancer type.
Diagnostic efficiency: Median time of 39.5 days from test results to cancer diagnosis.
Broad applicability: Proven feasibility across multiple healthcare settings, including private practices, healthcare systems and telemedicine.
“This research represents a significant step forward in the fight against cancer,” said Dr. Matrana. “The Galleri® test has the potential to revolutionize cancer screening and early detection, improving outcomes and saving lives.”
By participating in this groundbreaking study, Ochsner continues to position itself as a leader in cutting-edge cancer research and precision medicine. The findings not only validate the clinical utility of the Galleri® test but also pave the way for its broader adoption, potentially transforming cancer screening for patients across the United States.
For more than 80 years, Ochsner has been dedicated to cancer research and new cancer therapy development, bringing innovations to treatment with more clinical trials than anywhere else in Louisiana. It is accredited by the Commission on Cancer of the American College of Surgeons, the American Society of Clinical Oncology, the American College of Radiology, the Foundation for the Accreditation of Cellular Therapy (Bone Marrow Transplant) and the National Accreditation Program for Breast Centers.
Cancer care at Ochsner is recognized by U.S. News & World Report, ranking as high performing in leukemia, lymphoma and myeloma treatment, and colon, lung and prostate cancer surgeries. The Ochsner Cancer Institute treats more than 40,000 patients each year and has cared for patients from all 50 states and 28 countries.
Individual care teams for Ochsner cancer patients include as many as 20 multidisciplinary specialists working together to provide high-quality treatment for patients. Ochsner continues to lead the way in advancing medical genetics and cancer prevention strategies. With three geneticists and 16 genetic counselors across multiple specialties, Ochsner has the only robust precision medicine program in Louisiana.
For more information about MCED, read the full study here: Nature Communications
About Ochsner Health
Ochsner Health is the leading nonprofit healthcare provider in Louisiana, Mississippi and across the Gulf South, delivering expert care at its 47 hospitals and more than 370 health and urgent care centers. Ochsner is nationally recognized for inspiring healthier lives and stronger communities through expertise, quality and digital connectivity. In 2024, more than 40,000 dedicated team members and 4,900 employed and affiliated physicians at Ochsner cared for 1.6 million people from every state in the nation and 63 countries. To learn more about how Ochsner empowers people to get well and stay well, visit www.ochsner.org.
